CN101422427A - Magnesium isoglycyrrhizinate cream and preparation method and use thereof - Google Patents
Magnesium isoglycyrrhizinate cream and preparation method and use thereof Download PDFInfo
- Publication number
- CN101422427A CN101422427A CNA2008101781898A CN200810178189A CN101422427A CN 101422427 A CN101422427 A CN 101422427A CN A2008101781898 A CNA2008101781898 A CN A2008101781898A CN 200810178189 A CN200810178189 A CN 200810178189A CN 101422427 A CN101422427 A CN 101422427A
- Authority
- CN
- China
- Prior art keywords
- magnesium isoglycyrrhetate
- water
- agent
- magnesium
- isoglycyrrhetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 239000006071 cream Substances 0.000 title claims description 9
- OJIXTCWHYBRFHL-LEEOIRFPSA-L magnesium (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aS,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Mg++].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O OJIXTCWHYBRFHL-LEEOIRFPSA-L 0.000 title 1
- 239000011777 magnesium Substances 0.000 claims abstract description 82
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 82
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 81
- 239000000758 substrate Substances 0.000 claims abstract description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 28
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 201000004624 Dermatitis Diseases 0.000 claims description 20
- 239000003921 oil Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- 229910021529 ammonia Inorganic materials 0.000 claims description 12
- 230000002421 anti-septic effect Effects 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical group CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000007766 cera flava Substances 0.000 claims description 6
- 239000012188 paraffin wax Substances 0.000 claims description 6
- 230000000149 penetrating effect Effects 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 208000010247 contact dermatitis Diseases 0.000 claims description 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 5
- 206010048768 Dermatosis Diseases 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 48
- -1 transdermal patch Substances 0.000 description 31
- 239000012153 distilled water Substances 0.000 description 30
- 238000003756 stirring Methods 0.000 description 28
- 239000006072 paste Substances 0.000 description 26
- 239000002674 ointment Substances 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 21
- 239000000463 material Substances 0.000 description 17
- 235000011187 glycerol Nutrition 0.000 description 16
- 239000012528 membrane Substances 0.000 description 13
- 239000002966 varnish Substances 0.000 description 13
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 12
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 12
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 12
- 239000011241 protective layer Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 10
- 229920002125 Sokalan® Polymers 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229960000935 dehydrated alcohol Drugs 0.000 description 9
- 229940040145 liniment Drugs 0.000 description 9
- 239000000865 liniment Substances 0.000 description 9
- 238000000465 moulding Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 8
- 229960004949 glycyrrhizic acid Drugs 0.000 description 8
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 8
- 235000019410 glycyrrhizin Nutrition 0.000 description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 229960001631 carbomer Drugs 0.000 description 7
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000001685 glycyrrhizic acid Substances 0.000 description 7
- 229940057995 liquid paraffin Drugs 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 229920002367 Polyisobutene Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920006267 polyester film Polymers 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 241000581650 Ivesia Species 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- 239000005030 aluminium foil Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960002242 chlorocresol Drugs 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000005038 ethylene vinyl acetate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003871 white petrolatum Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 229940044949 eucalyptus oil Drugs 0.000 description 3
- 239000010642 eucalyptus oil Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940048053 acrylate Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000010913 used oil Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical group 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003239 pyrrolones Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical class [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a magnesium isoglycyrrhetate emulsifiable paste preparation which contains the magnesium isoglycyrrhetate, a water-in-oil type substrate and a pH regulator; wherein, the weight of the magnesium isoglycyrrhetate accounts for 1 to 10 percent and the pH value is 6.5 to 8; an emulsifier used in the water-in-oil type substrate is span 80 and monostearin.
Description
The application is to be JIUYUE in 2005 28 days the applying date, and application number is 200510106110.7, and denomination of invention is divided an application for the application for a patent for invention of " magnesium isoglycyrrhetate external preparation and its production and application ".
Technical field
The present invention relates to the external preparation of magnesium isoglycyrrhetate, comprise ointment, emulsifiable paste, transdermal patch, membrane, liniment and varnish, also relate to its preparation method and the application on medicine.
Technical background
Glycyrrhizic acid has pharmacological actions such as antiinflammatory, antiallergic action, adjusting immunity, antibiont oxidation and mutation inhibiting.Once used diammonium glycyrrhizinate intravenously administrable treatment psoriasis and dermatitis clinically,, had good efficacy as eczema.The oral formulations of glycyrrhizic acid also be used for clinically treating dermatosis such as psoriasis, eczema as compound glycyrrhizin sheet (trade name beautiful can), but these glycyrrhizic acid preparations all has certain side effect, as water-sodium retention etc., has influenced the compliance of patient's medication.Still do not have glycyrrhizic acid topical application formulation products at present and ask the city.
Chinese patent application CN1381463 " a kind of new chemical compound magnesium isoglycyrrhetate and production method and purposes " discloses magnesium isoglycyrrhetate first, it is a pentacyclic triterpenoid, chemistry 18 α by name, 20 β-carboxyl-11-oxidation-positive oleanane-12-alkene-3 beta-yls-2-O-β-D-glucopyanosyl carboxyl-α-D-Fructus Vitis viniferae pyrans glycosides aldehydic acid magnesium.This magnesium isoglycyrrhetate is the magnesium salt of the optical isomer α body glycyrrhizic acid of natural glycyrrhizic acid, has the animal serum of prevention transaminase and raises, and the effect that alleviates hepatocellular degeneration, necrosis and the cellular infiltration that reduces inflammation can promote liver cell regeneration.Pharmacodynamics and toxicity test prove that its anti-liver injury effect is better than natural glycyrrhizic acid.Magnesium isoglycyrrhetate only has its injection in exploitation at present, is used for the treatment of hepatitis.Application number is that 200410041923.8 Chinese patent application " magnesium isoglycyrrhetate gel and its production and application " discloses the magnesium isoglycyrrhetate gel and can be used for the treatment of abnormality dermatosiss such as eczematous dermatitis.But because gel causes chapped skin easily, we have studied other the external preparation that is suitable for treating psoriasis and dermatitis to be not suitable for plump lichenization such as psoriasis local application, for example ointment, emulsifiable paste, transdermal patch, membrane, liniment and varnish, overcome above-mentioned defective, thereby finished the present invention.
Summary of the invention
The purpose of this invention is to provide several magnesium isoglycyrrhetate external preparation, comprise magnesium isoglycyrrhetate ointment, emulsifiable paste, transdermal patch, membrane, liniment and varnish.
The present invention discloses the preparation method of magnesium isoglycyrrhetate external preparation in addition.
Another purpose of the present invention is open magnesium isoglycyrrhetate external preparation treatment psoriasis, chronic eczema dermatitis, contact dermatitis and the dermopathic purposes of other abnormalitys.
Exterior-applied formulation of the present invention is active component with the magnesium isoglycyrrhetate, and dosage form comprises ointment, emulsifiable paste, transdermal patch, membrane, liniment and/or varnish.
Magnesium isoglycyrrhetate ointment of the present invention and emulsifiable paste contain the magnesium isoglycyrrhetate as active substance, corresponding substrate and pH regulator agent.Wherein ointment base is a water-soluble base.Water-soluble base is a polyethylene glycols, for example: Macrogol 4000, polyethylene glycol 6000, Macrogol 600, PEG400.
Emulsifiable paste matrix is a water-in-oil type, used oil phase is stearic acid, paraffin, Cera Flava, vegetable oil or higher alcohol, the used emulsifying agent of the emulsifiable paste of water-in-oil type is the fatty acid ester or the smooth class of fatty acid Pyrusussuriensis of calcium soap, lanoline, polyhydric alcohol, is preferably sorbester p17, glyceryl monostearate.
Can also according to circumstances add penetrating agent, wetting agent, antiseptic, stabilizing agent in above-mentioned ointment and the emulsifiable paste.
Can also add thickening agent in ointment and the emulsifiable paste, for example Cera Flava, stearic acid, liquid Paraffin, white vaseline.
The magnesium isoglycyrrhetate and the water-soluble base that are added with the pH regulator agent are mixed, stir condensation and just can obtain ointment of the present invention, according to circumstances add penetrating agent, wetting agent, antiseptic, stabilizing agent.If will add wetting agent, pH regulator agent and antiseptic, then preparation method is soluble in water for (1) adds an amount of pH regulator agent with magnesium isoglycyrrhetate, adds wetting agent and antiseptic again.If antiseptic is soluble in the wetting agent, can earlier antiseptic be dissolved in the wetting agent, again with Isoglycyrrhiza acid magnesium solution mixing.(2) it is even that heating in water bath makes the water-soluble base fusion.Then (1) and (2) is mixed, be stirred to condensation, promptly obtain magnesium isoglycyrrhetate ointment.
The preparation process that can enumerate is: 1, magnesium isoglycyrrhetate is added an amount of 10% ammonia and be dissolved in the distilled water, ethyl hydroxybenzoate is dissolved in glycerol, adds the water solublity azone behind the mixing, stirs evenly.2, Macrogol 4000 and PEG400 are mixed,, stir evenly being heated in the water-bath about 70 ℃.3, (1) is added in (2), be stirred to condensation, promptly obtain magnesium isoglycyrrhetate ointment.
The preparation method of emulsifiable paste is, (1) adds an amount of pH regulator agent with magnesium isoglycyrrhetate and is dissolved in distilled water and makes water; (2) oiliness disperse medium, thickening agent and emulsifying agent melting mixing are evenly made oil phase; (3) above-mentioned water is added in the oil phase, under certain bath temperature, be stirred to milky, at room temperature stir condensation again.Add antiseptic when being necessary,, add in water or the oil phase according to the dissolubility of antiseptic.
The preparation process that can enumerate is (1), magnesium isoglycyrrhetate is added an amount of 5% sodium hydroxide is dissolved in the distilled water, adds chlorocresol again to be heated to about 80 ℃ in water-bath, stirs and makes dissolving, is water.(2), be oil phase with Cera Flava, glyceryl monostearate, liquid Paraffin, white vaseline and sorbester p17, put in the evaporating dish, in water-bath, be heated to about 80 ℃, stir evenly.(3), under 80 ℃, water is slowly added in the oil phase, and in water-bath, constantly be stirred to the semi-solid that is creamy white, at room temperature be stirred to nearly condensation again, promptly obtain the magnesium isoglycyrrhetate emulsifiable paste.
Magnesium isoglycyrrhetate transdermal patch of the present invention is made up of backing layer, drug storing layer and protective layer, can increase transdermal speed and effect that release-controlled film and adhered layer are controlled medicine if necessary.
Drug storing layer is made up of active medicine magnesium isoglycyrrhetate, substrate and pH regulator agent, and described substrate is catablasm base material, gel, ointment, emulsifiable paste, solution, suspension or pressure sensitive adhesive (or claiming gluing skeleton).
Described gel is made by hydrophilic macromolecular compounds such as carbomer, polyvinyl alcohol, polyvidone, Polyethylene Glycol, methylcellulose, ethyl cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, hypromellose, carboxymethyl cellulose, sodium carboxymethyl cellulose, gelatin or sodium alginate.
Described pressure sensitive adhesive adopts and is made by polyisobutylene, polysiloxanes, acrylate, polyacrylic acid resin, natural rubber.
Described catablasm base material is to be made with cross-linking agent, cross-linking regulator, wetting agent by in hydrophilic macromolecule such as carbomer, polyvinyl alcohol, polyvidone, hypromellose, carboxymethyl cellulose, sodium carboxymethyl cellulose, gelatin, xanthan gum, sodium alginate, polyacrylic acid, the sodium polyacrylate one or more.Wherein cross-linking agent is alumina gel, aluminum sulfate, aluminum acetate, moisture aluminum chloride, aluminum glycinate etc., and cross-linking regulator is citric acid, lactic acid, tartaric acid, gluconic acid, stearic acid, oleic acid, EDTA etc.
Described ointment, emulsifiable paste matrix are ditto described.Described solution or suspension are solvent with water, ethanol, oil.
Described adhered layer is made up of pressure sensitive adhesive or above-mentioned catablasm base material, does not contain medicine or contains the part medicine as loading dose, and the pressure sensitive adhesive that contains the part medicine is also referred to as gluing skeleton.The available pressure-sensitive adhesive material of the present invention has: Polyisobutylene PSA, polysiloxanes pressure sensitive adhesive, acrylate pressure sensitive adhesive, natural rubber or the pressure sensitive adhesive that is made into by polyacrylic resin.
Described drug storing layer and adhered layer can add plasticizer.Plasticizer is selected from paraffin, vaseline, alcohols, long-chain fatty acid phthalate ester, can select one or more chemical compounds wherein for use.
Described release-controlled film is homogeneous membrane or microporous membrane, and available release-controlled film has ethylene-vinyl acetate copolymer film, polysiloxane film, polypropylene screen, cellulose acetate membrane, polychloroethylene film, polyethylene film and polyethylene terephthalate film.
Described backing layer is aluminium foil, polyethylene film, polystyrene film, polychloroethylene film, polypropylene screen, polyester film, polyethylene terephthalate film, aluminum-plastic composite membrane or non-woven fabrics.
The low material of described protective layer usable surface free energy is as the polyethylene film handled through paraffin or Organosilicon Release Agent, polystyrene film, polypropylene screen, polyester film, separate paper etc.
Transdermal patch of the present invention can be made enclosed type, compound membranous type, adhesive matrix type, the cataplasma type of filling.Preferred cataplasma type.Fill the step that case type manufacturing process comprises the preparation drug storing layer, fills drug storing layer and patch molding; The manufacturing process of compound membranous type comprises preparation drug storing layer, adhered layer and protective layer is compound, the step of patch molding; The manufacturing process of adhesive matrix type comprises the step of preparation drug storing layer, patch molding; The manufacturing process of cataplasma type comprises the step of preparation catablasm base material, preparation drug storing layer, patch molding.
Can add penetrating agent, wetting agent, antiseptic, stabilizing agent in the above-mentioned transdermal patch.
Penetrating agent of the present invention can be one or more mixture with any mixed in sulfoxide class, pyrrolones, azone and analog thereof, fatty acid and ester thereof, surfactant, alcohols, polyalcohols, terpenes, amide-type, cyclodextrin, aminoacid and ester thereof, macrocyclic compound, organic acid, the phospholipid etc., one or both mixture with any mixed in preferred alcohol, propylene glycol, azone (Azone), oleic acid, eucalyptus oil, menthol, the Mentholum.
Wetting agent of the present invention is one or more mixture with any mixed in glycerol, propylene glycol, ethylene glycol, Polyethylene Glycol, sorbitol, maltose alcohol, sodium carboxymethyl cellulose, polyvinylpyrrolidone or the hyaluronic acid etc.
In order to improve magnesium isoglycyrrhetate dissolubility in water, add the pH regulator agent, can be triethanolamine, ethylenediamine, lauryl amine, ammonia spirit, sodium bicarbonate, sodium hydroxide or potassium hydroxide etc., preferred ammonia.Control solution pH value is preferably 6.5-8 at 6-9.
Antiseptic of the present invention is one or more mixture with any mixed in ethanol, chlorocresol, thimerosal, sorbic acid, potassium sorbate, benzoic acid, sodium benzoate, chlorobutanol, methyl hydroxybenzoate, ethyl hydroxybenzoate, the propylparaben.
Stabilizing agent of the present invention is a metal-chelator, for example disodium EDTA, EDTA calcium complex disodium salt or diethylenetriamine pentaacetic acid.
The weight of magnesium isoglycyrrhetate accounts for 0.3～20.0% in described ointment, emulsifiable paste, the transdermal patch, preferred 1-10%, the weight of substrate accounts for 0.2～20.0%, the weight of penetrating agent accounts for 0.1～20.0%, the weight of wetting agent accounts for 5.0～40.0%, the weight of antiseptic accounts for 0.1～20.0%, and the weight of stabilizing agent accounts for 0.05～0.20%.
External preparation of the present invention also comprises membrane, liniment or varnish.
Magnesium isoglycyrrhetate and liniment are made up of medicine magnesium isoglycyrrhetate and filmogen.Membrane used film forming material is polyvinyl alcohol, ethylene-vinyl acetate copolymer, acrylic copolymer, cellulose derivative, gelatin, Lac, arabic gum, agar etc., and liniment used film forming material is polyvinyl alcohol, polyvinylpyrrolidone, ethyl cellulose, polyvinyl formal-acetal, polyvinyl butyral resin, collodion etc.
Membrane and liniment can add plasticizer, and used plasticizer is same as above.
Magnesium isoglycyrrhetate varnish of the present invention is made up of medicine magnesium isoglycyrrhetate and disperse medium.Disperse medium has water, ethanol, glycerol, oils and fats etc.Three kinds of solution-type, suspension type and emulsion-types are arranged.Magnesium isoglycyrrhetate solution-type varnish also is added with cosolvent, and used cosolvent is triethanolamine, ethylenediamine, lauryl amine, ammonia spirit, sodium bicarbonate, sodium hydroxide or potassium hydroxide etc.The suspension type varnish also is added with suspending agent, and used suspending agent is glycerol, arabic gum, sodium alginate, agar, cellulose family, carbopol, polyvidone, glucosan, sodium acrylate, silicon Bentonite, thixotrope etc.The emulsion-type varnish comprises oil-in-water type and water-in-oil type, wherein used oil phase is vegetable oil, liquid Paraffin, higher alcohol, dimethyl-silicon wet goods, the used emulsifying agent of oil-in-water type is the derivatives class of soda soap, triethanolamine soap class, fatty alcohol sulphuric acid (ester) sodium class (sodium lauryl sulphate), poly yamanashi esters or polyoxyethylene ether, the same emulsifiable paste of the used emulsifying agent of water-in-oil type.
The inventor has investigated the influence of factors such as light, heat (40 ℃), low temperature to magnesium isoglycyrrhetate external preparation stability of the present invention.The result is that every index there is no significant change, shows that the above quality of the pharmaceutical preparations of the present invention is stable.
Above magnesium isoglycyrrhetate external preparation of the present invention is easy to use, can improve patient's compliance.
Particularly transdermal patch is compared with gel, and cataplasma is pollution clothes not, can take off subsides at any time and use repeatedly, also is easy to control dosage.In addition, cataplasma is compared with the patch of other substrate, with skin the compatibility preferably and affinity is arranged, moisture retention is preferably arranged, easily make keratodermatitis softening, thereby help the absorption of medicine, and there is not pain when peeling off, good permeability, the skin allergy of no rubber cream.
Test below by pharmacological effect exterior-applied formulation of the present invention is described.
1. the influence that medicine of the present invention forms mouse tail scale granular layer
ICR is a mice, body weight 18 native 2g, ♂ ♀ half and half.Be divided into 4 groups at random, normal control group, ointment group, emulsifiable paste group and transdermal patch group, every group of 10 mices are smeared each medicine at mouse tail respectively, the normal control group is smeared substrate, and the about 0.05ml of consumption smears 1 every day, after smearing 15 days continuously, get rectangularly, use 10% formalin fixed, paraffin embedding apart from the about 2cm of root place tail skin one, HE dyeing, the afterbody scale of each mice of observation under optical microscope.The granular layer cell person that every scale has connection to embark on journey is called the scale that granular layer is arranged.Count the scale number that granular layer is arranged in per 100 scales, statistical procedures is carried out in the t check between administration group and matched group.
Experimental result: three kinds of dosage forms of medicine of the present invention all can significantly improve mouse tail scale granular layer and form number (P＜0.01).Experimental result sees Table 1.
Table 1. medicine of the present invention forms mouse tail scale granular layer to be influenced (x ± s, n=10)
| Group | Granular layer scale ratio (individual/100) is arranged | Rate of change (%) |
| The normal control group | 6.70±1.06 | |
| The ointment group | 10.10±2.81** | 50.75 |
| The emulsifiable paste group | 10.50±3.57** | 56.72 |
| The transdermal patch group | 10.30±2.36** | 53.73 |
*Compare with the normal control group p＜0.01
2. medicine of the present invention is to the splitted influence of mouse vagina epithelial cell
Getting ICR is the ♀ mice, body weight 18 native 2g, lumbar injection (IP) diethylstilbestrol for three days on end, each 0.2mg was divided into 3 groups, model control group with mice on the 4th day, ointment group and emulsifiable paste group, every group of 10 mices, each administration group is smeared medicine 0.05ml in mouse vagina, and model control group is smeared the substrate of equivalent.Once a day, for three days on end, behind the last medicine one hour, each organized mice IP colchicine 2mg/kg, kill mice behind the 6h, get the vagina specimen with 10% formalin fixed, paraffin embedding, HE dyeing, under optical microscope, count the mitosis number in 300 basal cells, convert out the mitosis number in per 100 basal cells, be referred to as mitotic index.Statistical procedures is carried out in the t check between administration group and matched group.
Experimental result: two kinds of dosage forms of drug ointment of the present invention and emulsifiable paste all can significantly reduce estrogen phase mouse vagina epithelial cell mitotic index (P＜0.01).Result of the test sees Table 2.
Table 2. medicine of the present invention to the splitted influence of mouse vagina epithelial cell (x ± s, n=10)
| Group | The vaginal epithelial cell mitotic index | Rate of change (%) |
| Model control group | 13.30±1.64 | |
| The ointment group | 10.00±1.83** | -24.81 |
| The emulsifiable paste group | 9.90±1.79** | -25.56 |
*Compare with model control group p＜0.01
3. medicine of the present invention is to the influence of contact dermatitis
BALB/C mice, body weight 18 native 2g.Be divided into 4 groups at random, every group of 10 mices, model control group, ointment group, emulsifiable paste group and transdermal patch group.Each organizes the mouse web portion unhairing, and 150 μ l are coated with abdominal part with 3% azolactone dehydrated alcohol-acetone (3:1) solution, and in sensitization ear two sides each 0.05ml of coating the previous days two, once a day, continuous 6 days, model control group gave the substrate of equivalent; After the sensitization the 7th day, be coated with two ear two sides with 20 μ l, 1% azolactone olive oil, measure before exciting and excite the thickness of back 24h.
Experimental result: the mice auricle swelling (P＜0.01) that three kinds of remarkable Yi Zhi azolactones of dosage forms energy of medicine of the present invention cause.Result of the test sees Table 3.
Table .3. medicine of the present invention to the influence of mice contact dermatitis (x ± s, n=10)
| Group | Auricle swelling degree μ m | Auricle edema suppression ratio (%) |
| Model control group | 155.20±25.33 | |
| The ointment group | 107.90±18.51 | 30.48 |
| The emulsifiable paste group | 103.00±21.50** | 33.63 |
| The transdermal patch group | 105.30±20.36** | 32.15 |
*Compare with model control group p＜0.01
4. to the effect of mice chronic dermatitis-eczema
The ICR mice, body weight 18 native 2g are divided into 5 groups at random, every group of 10 mices, normal control group, model control group, ointment group, emulsifiable paste group and transdermal patch group.Each is organized mice and is applied to back sensitization outward with 7%DNCB100 μ l, smears 1%DNCB5 μ l in the mouse right ear inboard behind the 5d and excites, and excites 1 time every 3d.The administration group is in exciting the back in the inboard coating of mouse right ear, the about 0.05ml of consumption, 2 times/d first.Each is organized in the 4th and excites back 72h to survey the mice ear degree with slide gauge respectively, repeats to survey 3 times at every turn, averages.Each group was got 6 mouse right ears respectively and is done the pathology section after experiment finished, HE dyeing, and calculating corium soaks into the inflammatory cell number.
Experimental result: three kinds of dosage forms of medicine of the present invention can both significantly suppress the mice auricle swelling (P＜0.01) that the DNCB repetitious stimulation causes, reduce the infiltration inflammatory cell number of ear epidermis and corium, alleviate chronic inflammation.Point out three kinds of dosage forms of medicine of the present invention that mice chronic dermatitis-eczema is had significant inhibitory effect.Result of the test sees Table 4,5.
Table .4 medicine of the present invention to the influence of mice chronic dermatitis-eczema (x ± s, n=10)
| Group | Auricle swelling degree μ m | Auricle edema suppression ratio (%) |
| The normal control group | 155.70±24.60** | |
| Model control group | 231.10±34.54 | |
| The ointment group | 181.60±28.06** | 21.42 |
| The emulsifiable paste group | 182.70±25.44** | 20.94 |
| The transdermal patch group | 181.10±18.49** | 21.64 |
*Compare with model control group p＜0.01
Table .5 medicine of the present invention to mouse ear corium soak into number of inflammatory cells (x ± s, n=6)
| Group | Number of inflammatory cells is (individual/mm 2) | Suppression ratio (%) |
| Model control group | 94.83±10.28 | |
| The ointment group | 54.00±9.12** | 43.06 |
| The emulsifiable paste group | 55.50±8.26** | 41.48 |
| The transdermal patch group | 55.83±6.24** | 41.12 |
*Compare with model control group p＜0.01
Pharmacodynamics test shows, three kinds of dosage forms of medicine of the present invention can significantly improve mouse tail scale granular layer and form, significantly suppress estrogen phase mouse vagina epithelial cell mitosis, point out it to have the parakeratosis of correction and antimitotic effect, psoriasis is had the treatment meaning.Three kinds of dosage forms of medicine of the present invention can also significantly alleviate the ear swelling degree of contact dermatitis, chronic dermatitis-eczema mice, alleviate the chronic inflammatory disease performance of animal pattern ear epidermis and corium, reduce and soak into the inflammatory cell number, point out its effect, acute and chronic dermatitis, eczema class dermatosis are had the auxiliary treatment effect with antiinflammatory, anti-allergy action and adjusting body's immunity.
The specific embodiment
Be that the basis describes the present invention in detail below with embodiments of the invention, but the present invention is not limited to this.
Embodiment 1: water-soluble base type ointment
Prescription (200g):
Magnesium isoglycyrrhetate 2g
Macrogol 4000 60g
PEG400 90g
Water solublity azone 4g
Ethyl hydroxybenzoate 0.2g
10% ammonia is an amount of
Glycerol 10g
Distilled water is mended to 200g
Method for making: 1, magnesium isoglycyrrhetate is added an amount of 10% ammonia and be dissolved in the distilled water, ethyl hydroxybenzoate is dissolved in glycerol, adds the water solublity azone behind the mixing, stirs evenly.
2, Macrogol 4000 and PEG400 are mixed,, stir evenly being heated in the water-bath about 70 ℃.
3, (1) is added in (2), moisturizing is stirred to condensation to 200g, promptly.
Embodiment 2: the water-in-oil type emulsifiable paste
Prescription (200g):
Magnesium isoglycyrrhetate 2g
Sorbester p17 4g
Chlorocresol 0.4g
Cera Flava 15g
Liquid Paraffin 50g
White vaseline 10g
Glyceryl monostearate 30g
5% sodium hydroxide is an amount of
Distilled water 88g
Method for making: be oil phase 1,, put in the evaporating dish, be heated in the water-bath about 80 ℃ with Cera Flava, glyceryl monostearate, liquid Paraffin, white vaseline and sorbester p17.
2, magnesium isoglycyrrhetate is added an amount of 5% sodium hydroxide and be dissolved in the distilled water, add chlorocresol,, stir and make dissolving, be water in also being heated in the water-bath about 80 ℃.
3, under about 80 ℃, water is slowly added in the oil phase, and in water-bath, constantly be stirred to the semi-solid that is creamy white, at room temperature be stirred to nearly condensation again, promptly.
Embodiment 3: fill enclosed type magnesium isoglycyrrhetate transdermal patch
The described patch of present embodiment is made up of backing layer, drug storing layer, release-controlled film, adhered layer and protective layer.Each layer material therefor is as follows:
Backing layer: aluminium foil/polyethylene composite film
Protective layer: polyester film
Release-controlled film: ethylene-vinyl acetate copolymer film
Adhered layer: polysiloxanes pressure sensitive adhesive
Drug storing layer (200g):
Magnesium isoglycyrrhetate 20g
Carbomer 4g
Triethanolamine is an amount of
Glycerol 20g
Azone 4g
5% sodium hydroxide is an amount of
Distilled water adds to 200g
Method for making:
1, preparation drug storing layer:
(1) under agitation carbomer is slowly added in the distilled water of amount of preparation 50%, make its abundant swelling.After treating the carbomer complete swelling, add triethanolamine, regulate pH to 7.0, add azone and glycerol then, fully stir.
(2), magnesium isoglycyrrhetate added an amount of 5% sodium hydroxide be dissolved in the distilled water, stir evenly.
(3) (2) are added in (1), fully stir, and adding distil water stir promptly to capacity.
2, fill drug storing layer:
Drug storing layer quantitatively is added between aluminium foil/polyethylene composite film and the ethylene-vinyl acetate copolymer film heat seal sealing by the calibrated shot pump.
3, patch molding:
On polyester film, coat the polysiloxanes pressure sensitive adhesive, compound with (2) again, i.e. molding.
Embodiment 4: compound membranous type magnesium isoglycyrrhetate transdermal patch
The described patch of present embodiment is made up of backing layer, drug storing layer, release-controlled film, adhered layer and protective layer.Each layer material therefor is as follows:
Backing layer: aluminium foil/polyethylene composite film
Protective layer: polystyrene film
Release-controlled film: microporous polypropylene membrane
Adhered layer: Polyisobutylene PSA
Drug storing layer (200g):
Magnesium isoglycyrrhetate 5g
Polyisobutylene PSA 100g
Liquid Paraffin 20g
Azone 8g
5% sodium bicarbonate is an amount of
Dehydrated alcohol 8g
Distilled water adds to 200g
Method for making:
1, preparation drug storing layer:
Magnesium isoglycyrrhetate is added an amount of 5% sodium bicarbonate be dissolved in the distilled water, azone is dissolved in the dehydrated alcohol, mixing both, add liquid Paraffin and Polyisobutylene PSA, fully stir, and adding distil water is mixed well to capacity.Be coated on then on aluminium foil/polyethylene composite film, the thickness of control coating, 60 ℃ of oven dry cover microporous polypropylene membrane the drug storing layer surface then.
2, adhered layer and protective layer are compound:
Polyisobutylene PSA is coated on the polystyrene film 60 ℃ of oven dry.
3, patch molding:
(1) and (2) are compound, cutting, packing, promptly.
Embodiment 5: adhesive matrix type magnesium isoglycyrrhetate transdermal patch
The described patch of present embodiment is made up of backing layer, drug storing layer and protective layer.Each layer material therefor is as follows:
Backing layer: polyester film
Protective layer: separate paper
Drug storing layer (200g):
Magnesium isoglycyrrhetate 2g
Polyacrylate pressure-sensitive 120g
Eucalyptus oil 10g
Dehydrated alcohol adds to 200g
Method for making:
1, preparation drug storing layer:
Magnesium isoglycyrrhetate was pulverized 100 mesh sieves, then itself and eucalyptus oil were added the dehydrated alcohol dispersing and dissolving, added polyacrylate pressure-sensitive again, and weighed after stirring evenly and add dehydrated alcohol, mixed well to capacity, stand-by.
2, patch molding:
Drug storing layer is coated on the polyester film, the thickness of control coating, 60 ℃ of oven dry cover and go up separate paper, cutting, packing, promptly.
Embodiment 6: cataplasma type magnesium isoglycyrrhetate transdermal patch
The described patch of present embodiment is made up of backing layer, drug storing layer and protective layer.Each layer material therefor is as follows:
Backing layer: non-woven fabrics
Protective layer: separate paper
Drug storing layer (200g):
Magnesium isoglycyrrhetate 2g
Carbomer 2g
Sodium polyacrylate 4.8g
Moisture aluminum chloride 0.4g
Citric acid 0.8g
Glycerol 20g
Menthol 8g
5% potassium hydroxide is an amount of
Dehydrated alcohol 10g
Distilled water adds to 200g
Method for making:
1, preparation catablasm base material:
(1) carbomer is dispersed in the distilled water, stirs and make its swelling.
(2) sodium polyacrylate is dispersed in the aqueous solution of glycerol.
(3) citric acid and aluminum chloride are dissolved in distilled water.
(4) (2) are added in (3), stir evenly.Again (1) is added wherein, stir evenly, stand-by.
2, preparation drug storing layer: magnesium isoglycyrrhetate is added an amount of 5% potassium hydroxide be dissolved in the distilled water, menthol is dissolved in the dehydrated alcohol, mixing both, add in the blank catablasm base material, fully stir, and adding distil water stirs promptly to capacity, stand-by.
3, patch molding: above-mentioned drug storing layer is coated on the non-woven fabrics, and the thickness of control coating covers separate paper, cutting, and packing, promptly.
Embodiment 7: the magnesium isoglycyrrhetate membrane
Prescription (200g):
Magnesium isoglycyrrhetate 4g
Polyvinyl alcohol 60g
Glycerol 5g
10% ammonia is an amount of
Distilled water adds to 200g
Method for making: 1, magnesium isoglycyrrhetate is added an amount of 10% ammonia and be dissolved in the distilled water, add glycerol, stir evenly, add polyvinyl alcohol, placement is spent the night.
2, treat the complete moistening expansion of polyvinyl alcohol after, put 65 ℃ of heating in water bath to all dissolvings, ultrasonic degas makes the air ease to the greatest extent, coating materials.
3, coating materials is poured into synthermal glass plate lower edge, promoted coating materials forward with push rod and transfer to thickness 0.07mm, move to baking oven through 70 ℃ of forced air dryings demoulding immediately after 10 minutes, cooling, cutting, packing, promptly.
Embodiment 8: the magnesium isoglycyrrhetate liniment
Prescription (200g):
Magnesium isoglycyrrhetate 2g
Polyvinyl alcohol 8g
Glycerol 20g
Azone 3g
Distilled water 60g
Dehydrated alcohol 105g
Method for making: 1, get polyvinyl alcohol and add in glycerol and the distilled water after the complete moistening expansion, put 65 ℃ of heating in water bath to all dissolvings.
2, get magnesium isoglycyrrhetate and pulverized 100 mesh sieves, add dehydrated alcohol and be uniformly dispersed, add azone, stir evenly.
3, (2) are slowly added in (1), the limit edged stirs, and stirs evenly back packing rapidly, and is airtight, promptly.
Embodiment 9: aqueous solution type magnesium isoglycyrrhetate varnish
Prescription (200g):
Magnesium isoglycyrrhetate 4g
5% sodium bicarbonate is an amount of
Ethyl hydroxybenzoate 0.2g
Distilled water adds to 200g
Method for making: ethyl hydroxybenzoate is added in the distilled water, and the suitably short dissolving of heating adds magnesium isoglycyrrhetate then, adds an amount of 5% sodium bicarbonate after the agitation as appropriate and makes the dissolving clarification, and add distilled water to capacity, stirs evenly, and packing, promptly.
Embodiment 10: suspension type magnesium isoglycyrrhetate varnish
Prescription (200g):
Magnesium isoglycyrrhetate 20g
Hypromellose 2g
Ethyl hydroxybenzoate 0.2g
Glycerol 80g
Distilled water adds to 200g
Method for making: ethyl hydroxybenzoate and hypromellose are added in distilled water and the glycerol, and the suitably short dissolving of heating adds the magnesium isoglycyrrhetate of pulverizing and crossing 100 mesh sieves then, weighs after fully stirring and adds distilled water to capacity, stir evenly, and packing, promptly.
Embodiment 11: oil-in-water type magnesium isoglycyrrhetate varnish
Prescription (200g):
Magnesium isoglycyrrhetate 4g
Tween 80 10g
Ethyl hydroxybenzoate 0.2g
Soybean oil 40g
Distilled water adds to 200g
Method for making: 1, magnesium isoglycyrrhetate was pulverized 100 mesh sieves, and mixed with Tween 80, ethyl hydroxybenzoate and distilled water then.
2, pour soybean oil into colloid mill, again (1) is poured into, open colloid mill, until the uniform emulsion of formation, packing, promptly.
Embodiment 12: water-in-oil type magnesium isoglycyrrhetate varnish
Prescription (200g):
Magnesium isoglycyrrhetate 10g
Sorbester p17 6g
Ethyl hydroxybenzoate 0.2g
Soybean oil 120g
10% ammonia is an amount of
Distilled water 63g
Method for making: 1, magnesium isoglycyrrhetate is added an amount of 10% ammonia and be dissolved in the distilled water, add ethyl hydroxybenzoate then, suitably heating makes dissolving, stirs evenly.
2, pour soybean oil and sorbester p17 into colloid mill, again (1) is poured into, open colloid mill, until the uniform emulsion of formation, packing, promptly.
Claims (6)
1, a kind of magnesium isoglycyrrhetate cream preparation comprises magnesium isoglycyrrhetate, water-in-oil type substrate and pH regulator agent, and wherein the weight of magnesium isoglycyrrhetate accounts for 1-10%, and pH value is 6.5-8, and used emulsifying agent is sorbester p17, glyceryl monostearate in the water-in-oil type substrate.
2, the magnesium isoglycyrrhetate cream preparation of claim 1, wherein the oil phase in the water-in-oil type substrate is stearic acid, paraffin, Cera Flava, vegetable oil or higher alcohol.
3, claim 1 or 2 magnesium isoglycyrrhetate cream preparation, wherein the pH regulator agent is triethanolamine, ethylenediamine, lauryl amine, ammonia, sodium bicarbonate, sodium hydroxide or potassium hydroxide.
4, the magnesium isoglycyrrhetate cream preparation of claim 3, wherein the pH regulator agent is an ammonia.
5, claim 1 or 2 magnesium isoglycyrrhetate cream preparation also comprise penetrating agent, wetting agent, antiseptic or stabilizing agent.
6, the application of the magnesium isoglycyrrhetate cream preparation of claim 1 in preparation treatment psoriasis, chronic eczema dermatitis, contact dermatitis and other abnormality dermatosis treating medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101781898A CN101422427B (en) | 2005-09-28 | 2005-09-28 | Magnesium isoglycyrrhizinate cream and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101781898A CN101422427B (en) | 2005-09-28 | 2005-09-28 | Magnesium isoglycyrrhizinate cream and preparation method and use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101061107A Division CN100544730C (en) | 2005-09-28 | 2005-09-28 | Magnesium isoglycyrrhetate external preparation and its production and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101422427A true CN101422427A (en) | 2009-05-06 |
| CN101422427B CN101422427B (en) | 2011-06-22 |
Family
ID=40613456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101781898A Active CN101422427B (en) | 2005-09-28 | 2005-09-28 | Magnesium isoglycyrrhizinate cream and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101422427B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370585A (en) * | 2010-08-17 | 2012-03-14 | 舒朝锋 | Gel mask matrix and preparation technology thereof |
| CN103242392A (en) * | 2012-02-13 | 2013-08-14 | 南京华狮化工有限公司 | Novel glycyrrhizic acid double salt, and preparation and application thereof |
| CN103735494A (en) * | 2014-01-14 | 2014-04-23 | 山东司邦得制药有限公司 | External antipruritic ointment for treating mosquito bite and preparation method of external antipruritic ointment |
| CN106309353A (en) * | 2015-06-19 | 2017-01-11 | 江苏吉贝尔药业股份有限公司 | Ointment used for treating psoriasis and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381124C (en) * | 2004-09-09 | 2008-04-16 | 江苏正大天晴药业股份有限公司 | Magnesium iso-glycyrrhetate gel and its preparing method and use |
-
2005
- 2005-09-28 CN CN2008101781898A patent/CN101422427B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370585A (en) * | 2010-08-17 | 2012-03-14 | 舒朝锋 | Gel mask matrix and preparation technology thereof |
| CN103242392A (en) * | 2012-02-13 | 2013-08-14 | 南京华狮化工有限公司 | Novel glycyrrhizic acid double salt, and preparation and application thereof |
| CN103242392B (en) * | 2012-02-13 | 2016-04-13 | 南京华狮化工有限公司 | A kind of glycyrrhizic acid double salt and preparation and application thereof |
| CN103735494A (en) * | 2014-01-14 | 2014-04-23 | 山东司邦得制药有限公司 | External antipruritic ointment for treating mosquito bite and preparation method of external antipruritic ointment |
| CN103735494B (en) * | 2014-01-14 | 2015-07-01 | 山东司邦得制药有限公司 | External antipruritic ointment for treating mosquito bite and preparation method of external antipruritic ointment |
| CN106309353A (en) * | 2015-06-19 | 2017-01-11 | 江苏吉贝尔药业股份有限公司 | Ointment used for treating psoriasis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101422427B (en) | 2011-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100544730C (en) | Magnesium isoglycyrrhetate external preparation and its production and application | |
| CN112316205A (en) | External asiaticoside gel dressing and preparation method thereof | |
| CN101468138A (en) | Gel patch for treating insomnia and method for preparing the same | |
| CN101422427B (en) | Magnesium isoglycyrrhizinate cream and preparation method and use thereof | |
| CN103239389A (en) | Preparation method of progestin sustained-release gel for treating threatened abortion | |
| CN101455654B (en) | Arginine ibuprofen gel and preparation method thereof | |
| CN115414338A (en) | Micro-emulsified high-viscosity stable gel plaster matrix and preparation method thereof | |
| CN113712977A (en) | Cliboroluo external preparation and preparation method and application thereof | |
| CN102342914A (en) | Calcipotriol solid lipid nanoparticle and preparation method of same | |
| CN100391480C (en) | Hydrophilic gel pleximetric paste and its preparation | |
| CN101756886A (en) | Imiquimod micro emulsion gels for local skin and preparation method thereof | |
| CN102293735A (en) | Antifungal imidazole medicament controlled-release gel and preparation method thereof | |
| CN101278948A (en) | Biological medical membrane and method of preparing the same | |
| CN101991585B (en) | Percutaneous absorption film coating agent for treating rheumatoid arthritis and preparation method thereof | |
| CN112370420A (en) | Medicinal gel and preparation method and application thereof | |
| WO2005110358A2 (en) | Film-shaped estriol-containing medicament for oral administration | |
| CN100381124C (en) | Magnesium iso-glycyrrhetate gel and its preparing method and use | |
| CN101618030B (en) | Triptolide transdermal patch and preparation method thereof | |
| CN101468074A (en) | Antalgic gel patch and preparation method thereof | |
| CN102423293B (en) | Microemulsion gel preparation of oxiconazole nitrate | |
| CN105147827B (en) | A kind of antibacterial medicines and preparation method thereof | |
| CN102085199B (en) | Percutaneous absorption biological patch for treating rheumatoid arthritis and preparing method thereof | |
| CN105411998B (en) | The topical composition for the treatment of burn and scald containing deoxyschizandrin | |
| CN101468059A (en) | Gel patch for treating myopia and preparation method thereof | |
| CN102652730A (en) | Ointment base, kuh-seng and green tea ointment and preparation method of ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: JIANGSU CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Country or region after: China Address before: 222006 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Country or region before: China |